Epigenetic dysregulation in glioma
Article first published online: 24 MAR 2014
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 105, Issue 4, pages 363–369, April 2014
How to Cite
Cancer Sci 105 (2014) 363–369
- Issue published online: 11 APR 2014
- Article first published online: 24 MAR 2014
- Accepted manuscript online: 14 FEB 2014 04:05PM EST
- Manuscript Accepted: 8 FEB 2014
- Manuscript Revised: 7 FEB 2014
- Manuscript Received: 15 JAN 2014
- PRESTO of Japan Science and Technology Agency (JST)
- Japan Society for the Promotion of Science. Grant Number: 25290048
- Glioma stem cell;
- DNA methylation;
- histone modification;
- non-coding RNA
Given that treatment options for patients with glioblastoma are limited, much effort has been made to clarify the underlying mechanisms of gliomagenesis. Recent genome-wide genomic and epigenomic analyses have revealed that mutations in epigenetic modifiers occur frequently in gliomas and that dysregulation of epigenetic mechanisms is closely associated with glioma formation. Given that epigenetic changes are reversible, understanding the epigenetic abnormalities that arise in gliomagenesis might be key to developing more effective treatment strategies for glioma. In this review, we focus on the recent advancements in epigenetic research with respect to gliomas, consider how epigenetic mechanisms dynamically regulate tumor cells, including the cancer stem cell population, and discuss perspectives and challenges for glioma treatment in the near future.